CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients

被引：19

作者：

Chavaz, Lara ^{[1
]}

Royston, Lena ^{[1
]}

Masouridi-Levrat, Stavroula ^{[2
,3
]}

Mamez, Anne-Claire ^{[2
,3
]}

Giannotti, Federica ^{[2
,3
]}

Morin, Sarah ^{[2
,3
]}

Van Delden, Christian ^{[1
]}

Chalandon, Yves ^{[2
,3
]}

Neofytos, Dionysios ^{[1
]}

机构：

[1] Univ Hosp Geneva, Div Infect Dis, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva, Switzerland

[2] Univ Hosp Geneva, Div Hematol, Bone Marrow Transplant Unit, Geneva, Switzerland

[3] Univ Geneva, Fac Med, Geneva, Switzerland

来源：

OPEN FORUM INFECTIOUS DISEASES | 2023年 / 10卷 / 04期

关键词：

allogeneic hematopoietic cell transplant recipients (allo-HCTr); breakthrough infection; cytomegalovirus (CMV); letermovir; prophylaxis; risk factors; CYTOMEGALOVIRUS; DISEASE; SOCIETY;

D O I：

10.1093/ofid/ofad169

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In this single-center study of 61 allogeneic hematopoietic cell transplant (HCT) recipients receiving letermovir primary cytomegalovirus (CMV) prophylaxis for the first 100 days, we report 23% incidence of clinically significant CMV infection during the first 100 days after letermovir discontinuation, predominately in haploidentical HCT recipients, without any associations with CMV-DNAemia under letermovir.

引用

页数：5

共 21 条

[1] A review of infectious complications after haploidentical hematopoietic stem cell transplantations [J].

Atilla, Erden ;

Atilla, Pinar Ataca ;

Bozdag, Sinem Civriz ;

Demirer, Taner .

INFECTION, 2017, 45 (04) :403-411

[2] Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study [J].

Beauvais, David ;

Drumez, Elodie ;

Blaise, Didier ;

de Latour, Regis Peffault ;

Forcade, Edouard ;

Ceballos, Patrice ;

Uyttebroeck, Anne ;

Labussiere, Helene ;

Nguyen, Stephanie ;

Bourhis, Jean-Henri ;

Chevallier, Patrice ;

Thiebaut, Anne ;

Poir, Xavier ;

Maury, Sebastien ;

Deconinck, Eric ;

Cluzeau, Thomas ;

Brissot, Eolia ;

Huynh, Anne ;

Rubio, Marie-Therese ;

Duhamel, Alain ;

Yakoub-Agha, Ibrahim .

BONE MARROW TRANSPLANTATION, 2021, 56 (06) :1305-1315

[3] Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity [J].

Boeckh, M ;

Leisenring, W ;

Riddell, SR ;

Bowden, RA ;

Huang, ML ;

Myerson, D ;

Stevens-Ayers, T ;

Flowers, MED ;

Cunningham, T ;

Corey, L .

BLOOD, 2003, 101 (02) :407-414

[4] Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection [J].

Cassaniti, Irene ;

Colombo, Anna A. ;

Bernasconi, Paolo ;

Malagola, Michele ;

Russo, Domenico ;

Iori, Anna P. ;

Girmenia, Corrado ;

Greco, Raffaella ;

Peccatori, Jacopo ;

Ciceri, Fabio ;

Bonifazi, Francesca ;

Percivalle, Elena ;

Campanini, Giulia ;

Piccirilli, Giulia ;

Lazzarotto, Tiziana ;

Baldanti, Fausto .

AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 (04) :1622-1628

[5] Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study [J].

Chemaly, Roy F. ;

El Haddad, Lynn ;

Winston, Drew J. ;

Rowley, Scott D. ;

Mulane, Kathleen M. ;

Chandrasekar, Pranatharthi ;

Avery, Robin K. ;

Hari, Parameswaran ;

Peggs, Karl S. ;

Kumar, Deepali ;

Nath, Rajneesh ;

Ljungman, Per ;

Mossad, Sherif B. ;

Dadwal, Sanjeet S. ;

Blanchard, Ted ;

Shah, Dimpy P. ;

Jiang, Ying ;

Ariza-Heredia, Ella .

CLINICAL INFECTIOUS DISEASES, 2020, 71 (09) :2365-2374

[6] The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients [J].

El Haddad, Lynn ;

Ariza-Heredia, Ella ;

Shah, Dimpy P. ;

Jiang, Ying ;

Blanchard, Ted ;

Ghantoji, Shashank S. ;

El Chaer, Firas ;

El-Haddad, Danielle ;

Prayag, Amrita ;

Nesher, Lior ;

Rezvani, Katy ;

Shpall, Elizabeth ;

Chemaly, Roy F. .

JOURNAL OF INFECTIOUS DISEASES, 2019, 219 (06) :898-907

[7] Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies [J].

Gao, Xiao-Ning ;

Lin, Ji ;

Wang, Li-Jun ;

Li, Fei ;

Li, Hong-Hua ;

Wang, Shu-Hong ;

Huang, Wen-Rong ;

Gao, Chun-Ji ;

Yu, Li ;

Liu, Dai-Hong .

ANNALS OF HEMATOLOGY, 2020, 99 (08) :1883-1893

[8] American Society for Transplantation and Cellular Therapy Series: #3-Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation [J].

Hakki, Morgan ;

Aitken, Samuel L. ;

Danziger-Isakov, Lara ;

Michaels, Marian G. ;

Carpenter, Paul A. ;

Chemaly, Roy F. ;

Papanicolaou, Genovefa A. ;

Boeckh, Michael ;

Marty, Francisco M. .

TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (09) :707-719

[9] Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia [J].

Lin, Cheng-Hsien ;

Su, Yi-Jiun ;

Hsu, Chiann-Yi ;

Wang, Po-Nan ;

Teng, Chieh-Lin Jerry .

TRANSPLANT INFECTIOUS DISEASE, 2019, 21 (04)

[10]

Liu LW., 2022, TRANSPLANT CELL THER, V28, P510

← 1 2 3 →